Physician profile
Robert B Coye
NPI 1215066170
$1,025.54
in general payments reported to CMS, 2019-2025
20 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $12.49 · 2021: $99.74 · 2022: $244 · 2023: $167 · 2024: $160 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $132.23 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.01 | 2022 | |
| Amgen INC. | $115.04 | 2022-2025 | Repatha, Otezla, Otezla |
| Boston Scientific Corporation | $114.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.14 | 2021-2025 | Trintellix, Vpriv |
| Abbvie INC. | $96.98 | 2021-2023 | Ubrelvy |
| Glaxosmithkline, LLC. | $55.20 | 2020-2023 | Shingrix, Arexvy |
| Lilly USA, LLC | $45.78 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $31.87 | 2023-2024 | Breztri |
| Pfizer INC. | $26.77 | 2019 | |
| Abiomed | $24.52 | 2025 | |
| Esperion Therapeutics, INC. | $21.08 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.41 | 2022 | |
| Edwards Lifesciences Corporation | $18.61 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $18.28 | 2024 | Imcivree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.67 | 2024 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $17.05 | 2024 | Evkeeza |
| Amneal Pharmaceuticals LLC | $16.43 | 2024 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.38 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Coye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.